{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:13:59Z","timestamp":1790356439159,"version":"4.1.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 AI1222669, R01 AI148264, R21 AI124672"],"award-info":[{"award-number":["R01 AI1222669, R01 AI148264, R21 AI124672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["GM111158"],"award-info":[{"award-number":["GM111158"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005187","name":"National and Kapodistrian University of Athens","doi-asserted-by":"publisher","award":["15725"],"award-info":[{"award-number":["15725"]}],"id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"publisher"}]},{"name":"School of Medicine and the Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine"},{"name":"School of Medicine and the Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine"},{"name":"School of Medicine and the Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine"},{"name":"McNair Scholars Program"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>\n                    Rift Valley fever virus (RVFV) is a veterinary and human pathogen and is an agent of bioterrorism concern. Currently, RVFV treatment is limited to supportive care, so new drugs to control RVFV infection are urgently needed. RVFV is a member of the order\n                    <jats:italic>Bunyavirales<\/jats:italic>\n                    , whose replication depends on the enzymatic activity of the viral L protein. Screening for RVFV inhibitors among compounds with divalent cation-coordinating motifs similar to known viral nuclease inhibitors identified 47 novel RVFV inhibitors with selective indexes from 1.1\u2013103 and 50% effective concentrations of 1.2\u201356 \u03bcM in Vero cells, primarily \u03b1-Hydroxytropolones and N-Hydroxypyridinediones. Inhibitor activity and selective index was validated in the human cell line A549. To evaluate specificity, select compounds were tested against a second Bunyavirus, La Crosse Virus (LACV), and the flavivirus Zika (ZIKV). These data indicate that the \u03b1-Hydroxytropolone and N-Hydroxypyridinedione chemotypes should be investigated in the future to determine their mechanism(s) of action allowing further development as therapeutics for RVFV and LACV, and these chemotypes should be evaluated for activity against related pathogens, including Hantaan virus, severe fever with thrombocytopenia syndrome virus, Crimean-Congo hemorrhagic fever virus.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0274266","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T13:36:06Z","timestamp":1663335366000},"page":"e0274266","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metal coordinating inhibitors of Rift Valley fever virus replication"],"prefix":"10.1371","volume":"17","author":[{"given":"Elizabeth","family":"Geerling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-0741","authenticated-orcid":true,"given":"Maria C.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Taylor","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu Gazquez","family":"Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariah","family":"Hassert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin T.","family":"O\u2019Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J.","family":"Donlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elagawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-7976","authenticated-orcid":true,"given":"Bahaa","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Pardali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erofili","family":"Giannakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigoris","family":"Zoidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V.","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana B.","family":"Agyemang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Murelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Tavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia K.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"issue":"6","key":"pone.0274266.ref001","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1040841X.2017.1307805","article-title":"Bunyaviridae RdRps: structure, motifs, and RNA synthesis machinery","volume":"43","author":"A Amroun","year":"2017","journal-title":"Crit Rev Microbiol"},{"issue":"2","key":"pone.0274266.ref002","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cll.2017.01.004","article-title":"Rift Valley Fever","volume":"37","author":"A. Hartman","year":"2017","journal-title":"Clin Lab Med"},{"issue":"5","key":"pone.0274266.ref003","first-page":"941","article-title":"Rainfall and epizootic Rift Valley fever","volume":"63","author":"FG Davies","year":"1985","journal-title":"Bull World Health Organ"},{"issue":"5426","key":"pone.0274266.ref004","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.285.5426.397","article-title":"Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya","volume":"285","author":"KJ Linthicum","year":"1999","journal-title":"Science"},{"issue":"3","key":"pone.0274266.ref005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1086\/345671","article-title":"Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans","volume":"36","author":"M Al-Hazmi","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0274266.ref006","article-title":"La Crosse Virus Infection of Human Keratinocytes Leads to Interferon-Dependent Apoptosis of Bystander Non-Infected Cells In Vitro","volume":"12","author":"MA Cruz","year":"2020","journal-title":"Viruses"},{"issue":"3","key":"pone.0274266.ref007","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1128\/jvi.49.3.680-685.1984","article-title":"Characterization of La Crosse virus small-genome transcripts","volume":"49","author":"JL Patterson","year":"1984","journal-title":"Journal of virology"},{"issue":"3","key":"pone.0274266.ref008","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4269\/ajtmh.21-0294","article-title":"La Crosse Virus Disease in the United States, 2003\u20132019","volume":"105","author":"GM Vahey","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0274266.ref009","unstructured":"ArboNET, Arboviral_Diseases_Branch, Centers_for_Disease_Control_and_Prevention. La Crosse Encephalitis; Statistics & Maps 2020. https:\/\/www.cdc.gov\/lac\/statistics\/index.html."},{"key":"pone.0274266.ref010","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3389\/fmicb.2015.00676","article-title":"Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection","volume":"6","author":"A Benedict","year":"2015","journal-title":"Front Microbiol"},{"key":"pone.0274266.ref011","doi-asserted-by":"crossref","first-page":"104854","DOI":"10.1016\/j.antiviral.2020.104854","article-title":"A small molecule inhibitor of MyD88 exhibits broad spectrum antiviral activity by up regulation of type I interferon","volume":"181","author":"KU Saikh","year":"2020","journal-title":"Antiviral Res"},{"issue":"7","key":"pone.0274266.ref012","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"MC Wolf","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pone.0274266.ref013","doi-asserted-by":"crossref","first-page":"e0171321","DOI":"10.1128\/jvi.01713-21","article-title":"Structure of Rift Valley Fever Virus RNA-Dependent RNA Polymerase","volume":"96","author":"X Wang","year":"2022","journal-title":"Journal of virology"},{"key":"pone.0274266.ref014","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.virusres.2017.01.013","article-title":"Structural insights into RNA synthesis by the influenza virus transcription-replication machine","volume":"234","author":"A Pflug","year":"2017","journal-title":"Virus Res"},{"issue":"2","key":"pone.0274266.ref015","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/embor.2008.256","article-title":"Retroviral integrase superfamily: the structural perspective","volume":"10","author":"M. Nowotny","year":"2009","journal-title":"EMBO Rep"},{"issue":"5","key":"pone.0274266.ref016","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/phar.2246","article-title":"Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?","volume":"39","author":"KM Brooks","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"14","key":"pone.0274266.ref017","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.2174\/0929867324666170113110839","article-title":"Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013\u20132016): Opportunities and Challenges","volume":"25","author":"X Wang","year":"2018","journal-title":"Curr Med Chem"},{"key":"pone.0274266.ref018","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1080\/14728222.2019.1619697","article-title":"Shedding light on RNaseH: a promising target for hepatitis B virus (HBV)","volume":"23","author":"TC Edwards","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"pone.0274266.ref019","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1060028019826565","article-title":"Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza","volume":"53","author":"T. Yang","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0274266.ref020","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"S Omoto","year":"2018","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0274266.ref021","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.str.2009.09.016","article-title":"Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site","volume":"17","author":"DM Himmel","year":"2009","journal-title":"Structure"},{"issue":"11","key":"pone.0274266.ref022","first-page":"702","article-title":"HIV-1 reverse transcriptase structure with RNase H inhibitor dihydroxy benzoyl naphthyl hydrazone bound at a novel site","volume":"1","author":"DM Himmel","year":"2006","journal-title":"ACS ChemBiol"},{"issue":"15","key":"pone.0274266.ref023","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1128\/JVI.00353-10","article-title":"Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors","volume":"84","author":"HP Su","year":"2010","journal-title":"JVirol"},{"key":"pone.0274266.ref024","first-page":"377","article-title":"Emerging pharmacology: inhibitors of human immunodeficiency virus integration","volume":"49","author":"D Hazuda","year":"2009","journal-title":"AnnuRevPharmacolToxicol"},{"issue":"12","key":"pone.0274266.ref025","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"M Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0274266.ref026","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"M Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0274266.ref027","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"S Min","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"5453","key":"pone.0274266.ref028","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1126\/science.287.5453.646","article-title":"Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells","volume":"287","author":"DJ Hazuda","year":"2000","journal-title":"Science"},{"key":"pone.0274266.ref029","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.3389\/fmicb.2018.03026","article-title":"Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil","volume":"9","author":"E Takashita","year":"2018","journal-title":"Front Microbiol"},{"key":"pone.0274266.ref030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acs.chemrev.8b00201","article-title":"Targeting Metalloenzymes for Therapeutic Intervention","volume":"119","author":"AY Chen","year":"2019","journal-title":"Chem Rev"},{"issue":"51","key":"pone.0274266.ref031","doi-asserted-by":"crossref","first-page":"19686","DOI":"10.1074\/jbc.RA118.004373","article-title":"Biochemical and structural studies reveal differences and commonalities among cap-snatching endonucleases from segmented negative-strand RNA viruses","volume":"293","author":"T Holm","year":"2018","journal-title":"J Biol Chem"},{"issue":"2","key":"pone.0274266.ref032","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0969-2126(01)00142-3","article-title":"Recombining the structures of HIV integrase, RuvC and RNase H","volume":"3","author":"W Yang","year":"1995","journal-title":"Structure"},{"issue":"11","key":"pone.0274266.ref033","doi-asserted-by":"crossref","first-page":"15125","DOI":"10.1021\/acsomega.8b01754","article-title":"Synthesis and Evaluation of Troponoids as a New Class of Antibiotics","volume":"3","author":"F Cao","year":"2018","journal-title":"ACS Omega"},{"issue":"23","key":"pone.0274266.ref034","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1021\/ol302892g","article-title":"An oxidopyrylium cyclization\/ring-opening route to polysubstituted alpha-hydroxytropolones","volume":"14","author":"C Meck","year":"2012","journal-title":"Organic letters"},{"key":"pone.0274266.ref035","doi-asserted-by":"crossref","first-page":"e02574","DOI":"10.1128\/AAC.02574-16","article-title":"Troponoids can inhibit growth of the human fungal pathogen Cryptococcus neoformans","volume":"61","author":"MJ Donlin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pone.0274266.ref036","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1039\/C7OB02453C","article-title":"Synthesis and biological assessment of 3,7-dihydroxytropolones","volume":"16","author":"DR Hirsch","year":"2017","journal-title":"Org Biomol Chem"},{"issue":"59","key":"pone.0274266.ref037","doi-asserted-by":"crossref","first-page":"34227","DOI":"10.1039\/C9RA06383H","article-title":"Divergent synthesis of a thiolate-based alpha-hydroxytropolone library with a dynamic bioactivity profile","volume":"9","author":"NB Agyemang","year":"2019","journal-title":"RSC Adv"},{"key":"pone.0274266.ref038","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.antiviral.2017.06.014","article-title":"Efficacy and cytotoxicity in cell culture of novel alpha-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H","volume":"144","author":"E Lomonosova","year":"2017","journal-title":"Antiviral Res"},{"issue":"31","key":"pone.0274266.ref039","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.tetlet.2018.06.063","article-title":"Amidation Strategy for Final-Step alpha-Hydroxytropolone Diversification","volume":"59","author":"AJ Berkowitz","year":"2018","journal-title":"Tetrahedron Lett"},{"key":"pone.0274266.ref040","unstructured":"Donlin MJ, Tavis JE, Murelli RP, Meyers MJ, inventorsPreparation of substituted cycloheptatrienones as antifungal compounds. PCT International Application WO 2017\u2013184752 patent WO 2017\u2013184752. 2017."},{"issue":"21","key":"pone.0274266.ref041","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.bmcl.2014.09.037","article-title":"Inhibition of the ANT(2\u2019\u2019)-Ia resistance enzyme and rescue of aminoglycoside antibiotic activity by synthetic alpha-hydroxytropolones","volume":"24","author":"DR Hirsch","year":"2014","journal-title":"Bioorganic & medicinal chemistry letters"},{"key":"pone.0274266.ref042","unstructured":"Tavis JE, Morrison LA, Murelli RP, inventorsPreparation of hydroxylated tropolone inhibitorsof nucleotidyl transferases in treatment of herpesvirus and hepatitis B. PCT International Application WO 2016\u2013201243 patent WO 2016\u2013201243. 2016."},{"issue":"5","key":"pone.0274266.ref043","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1021\/acs.biochem.5b01254","article-title":"Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors","volume":"55","author":"T Masaoka","year":"2016","journal-title":"Biochemistry"},{"issue":"11","key":"pone.0274266.ref044","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1002\/jmv.27230","article-title":"Selective estrogen receptor modulator, tamoxifen, inhibits Zika virus infection","volume":"93","author":"SF Grady","year":"2021","journal-title":"J Med Virol"},{"issue":"150","key":"pone.0274266.ref045","doi-asserted-by":"crossref","DOI":"10.3791\/59632","article-title":"Isolation and Quantification of Zika Virus from Multiple Organs in a Mouse","author":"JD Brien","year":"2019","journal-title":"J Vis Exp"},{"issue":"22","key":"pone.0274266.ref046","doi-asserted-by":"crossref","first-page":"12472","DOI":"10.1128\/JVI.01123-07","article-title":"Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation","volume":"81","author":"H Guo","year":"2007","journal-title":"Journal of virology"},{"key":"pone.0274266.ref047","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2019.02.005","article-title":"Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors","volume":"164","author":"TC Edwards","year":"2019","journal-title":"Antiviral Res"},{"key":"pone.0274266.ref048","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2016.06.005","article-title":"Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors","volume":"132","author":"JA Villa","year":"2016","journal-title":"Antiviral Res"},{"issue":"1","key":"pone.0274266.ref049","doi-asserted-by":"crossref","first-page":"15D.3.1","DOI":"10.1002\/9780471729259.mc15d03s31","article-title":"Propagation, Quantification, Detection, and Storage of West Nile Virus","volume":"31","author":"JD Brien","year":"2013","journal-title":"Current Protocols in Microbiology"},{"issue":"12","key":"pone.0274266.ref050","doi-asserted-by":"crossref","first-page":"e1009163","DOI":"10.1371\/journal.ppat.1009163","article-title":"mRNA induced expression of human angiotensin-converting enzyme 2 in mice for the study of the adaptive immune response to severe acute respiratory syndrome coronavirus 2","volume":"16","author":"M Hassert","year":"2020","journal-title":"PLoS Pathog"},{"issue":"1","key":"pone.0274266.ref051","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1002\/cpmc.92","article-title":"Rift Valley Fever Virus: Propagation, Quantification, and Storage","volume":"55","author":"MR Smith","year":"2019","journal-title":"Curr Protoc Microbiol"},{"key":"pone.0274266.ref052","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"D Scharton","year":"2014","journal-title":"Antiviral Res"},{"issue":"5","key":"pone.0274266.ref053","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0166-3542(86)90024-0","article-title":"Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator","volume":"6","author":"CJ Peters","year":"1986","journal-title":"Antiviral Res"},{"issue":"2","key":"pone.0274266.ref054","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1128\/AAC.04617-14","article-title":"Hydroxylated Tropolones Inhibit Hepatitis B Virus Replication by Blocking the Viral Ribonuclease H Activity","volume":"59","author":"G Lu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0274266.ref055","doi-asserted-by":"crossref","first-page":"104777","DOI":"10.1016\/j.antiviral.2020.104777","article-title":"Amide-containing alpha-hydroxytropolones as inhibitors of hepatitis B virus replication","volume":"177","author":"Q Li","year":"2020","journal-title":"Antiviral Res"},{"issue":"3","key":"pone.0274266.ref056","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/iai.33.3.848-853.1981","article-title":"Respiratory infectivity of a recently isolated Egyptian strain of Rift Valley fever virus","volume":"33","author":"JL Brown","year":"1981","journal-title":"Infect Immun"},{"issue":"2","key":"pone.0274266.ref057","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","article-title":"Present and future arboviral threats","volume":"85","author":"SC Weaver","year":"2010","journal-title":"Antiviral Res"},{"issue":"4","key":"pone.0274266.ref058","doi-asserted-by":"crossref","first-page":"e1006103","DOI":"10.1371\/journal.pcbi.1006103","article-title":"Allostery in the dengue virus NS3 helicase: Insights into the NTPase cycle from molecular simulations","volume":"14","author":"RB Davidson","year":"2018","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"pone.0274266.ref059","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C4MD00055B","article-title":"The biology and synthesis of alpha-hydroxytropolones","volume":"5","author":"C Meck","year":"2014","journal-title":"Medchemcomm"},{"issue":"4","key":"pone.0274266.ref060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tim.2019.12.006","article-title":"The Cap-Snatching Mechanism of Bunyaviruses","volume":"28","author":"S Olschewski","year":"2020","journal-title":"Trends Microbiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T13:37:20Z","timestamp":1663335440000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0274266"}},"subtitle":[],"editor":[{"given":"Kylene","family":"Kehn-Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0274266","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.03.10.483712","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}